Makers Laboratories cash flow

·Pharma & HealthChart ›
Latest FY26
Cash from operations
−₹2.0cr−₹1.6 cr in FY25
Capital spending
₹0.3cr−87.2% on FY25
Free cash flow
−₹2.3cr−₹4.0 cr in FY25
Cash from financing
₹1.7cr−₹14.6 cr in FY25
₹ crore except per share
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
Adjustments to reconcile profit — non-cash items
2.82.82.7—
0.50.91.4—
−0.1−0.1−0.1—
−0.5−0.0−0.5—
Changes in working capital
−2.83.2−2.84.0
−0.41.10.8−2.4
1.3−2.05.80.5
Cash from operating activities
−2.04.9−7.0−6.8
−1.4−1.1−2.7−1.0
0.60.40.30.4
−2.0−1.6−3.1−1.4
Cash from investing activities
0.32.42.74.5
0.50.00.50.5
0.00.10.10.1
0.316.1−2.0−3.6
Cash from financing activities
0.30.80.91.2
1.7−14.65.14.9
−0.0−0.00.0−0.0
Reference items
0.7−2.2−3.8−4.1
1.5%−5.1%−7.7%−9.7%
−2.3−4.0−5.8−5.9
−0.2−18.1−2.3—
−₹3.95−₹6.79−₹9.74−₹9.99
1.18×—0.44×0.22×
0.60.40.30.4
0.30.80.91.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MAKERSL₹189.18

Makers Laboratories Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹112 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation—2.72.82.8
+ Finance Costs—1.40.90.5
+ Interest Income—-0.1-0.1-0.1
+ Dividend Income—-0.5-0.0-0.5
Changes in Working Capital
+ Inventories4.0-2.83.2-2.8
+ Trade Receivables — Current-2.40.81.1-0.4
+ Trade Payables — Current0.55.8-2.01.3
Cash from Operating Activities
Profit Before Tax (per I/S)-6.8-7.04.9-2.0
Cash from Operations (pre-tax)-1.0-2.7-1.1-1.4
+ Income Taxes Paid0.40.30.40.6
Cash from Operating Activities-1.4-3.1-1.6-2.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)4.52.72.40.3
+ Dividends Received — Investing0.50.50.00.5
+ Interest Received — Investing0.10.10.10.0
Cash from Investing Activities-3.6-2.016.10.3
Cash from Financing Activities
+ Interest Paid1.20.90.80.3
Cash from Financing Activities4.95.1-14.61.7
Net Changes in Cash-0.00.0-0.0-0.0
Reference Items
EBITDA-4.1-3.8-2.20.7
EBITDA Margin %-9.72-7.66-5.141.45
Free Cash Flow (CFO − Capex)-5.9-5.8-4.0-2.3
Free Cash Flow to Equity—-2.3-18.1-0.2
Free Cash Flow per Basic Share-9.99-9.74-6.79-3.95
Cash Flow to Net Income0.220.44—1.18
Cash Paid for Taxes0.40.30.40.6
Cash Paid for Interest1.20.90.80.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.